The Spectranetics Corporation (NASDAQ:SPNC) Files An 8-K Regulation FD Disclosure
ITEM 7.01. Regulation FD Disclosure.
Spectranetics Corporation, a Delaware corporation (the Company),
plans to use in various meetings with institutional investors and
analysts is furnished as Exhibit 99.1 of this report.
report is being furnished and shall not be deemed filed for the
purpose of Section 18 of the Securities Exchange Act of 1934, as
amended (the Exchange Act), or otherwise subject to the
liabilities of that section. The information under Item 7.01 and
in Exhibit 99.1 of this report shall not be incorporated by
reference into any filing under the Securities Act of 1933, as
amended, or the Exchange Act, except as shall be expressly set
forth by specific reference in such a filing.
statements within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements are based on the
current beliefs and expectations of the Companys management and
are subject to significant risks and uncertainties. Actual
results may differ from those set forth in the forward-looking
statements. Factors that could cause the Companys actual results
to differ materially from those described in the forward-looking
statements can be found in the Companys Annual Report on Form
10-K for the year ended December 31, 2015, and 2016 quarterly
reports on Form 10-Q, which have been filed with the Securities
and Exchange Commission. The Company does not undertake to update
the forward-looking statements to reflect the impact of
circumstances or events that may arise after the date of the
forward-looking statements.
|
Exhibit No.
|
Description
|
|
99.1
|
The Spectranetics Corporation Management Presentation
dated January 11, 2017. |
About The Spectranetics Corporation (NASDAQ:SPNC)
The Spectranetics Corporation is a United States-based company, which develops, manufactures, markets and distributes medical devices used in minimally invasive procedures within the cardiovascular system. The Company’s products are available in over 65 countries and are used to cross, prepare and treat arterial blockages in the legs and heart, and to remove pacemaker and defibrillator cardiac leads. The Company’s segments include U.S. Medical and International Medical. The U.S. Medical segment offers medical devices, including fiber-optic devices and non-fiber-optic products (disposables), an excimer laser system (equipment), and the service of the excimer laser system (service). The International Medical segment serves Europe, the Middle East, Asia Pacific, Latin America and Puerto Rico, and provides Stellarex DCB and AngioSculptX products, which are available for sale in Europe. The Company’s solutions include Lead Management, Peripheral Intervention and Coronary Intervention. The Spectranetics Corporation (NASDAQ:SPNC) Recent Trading Information
The Spectranetics Corporation (NASDAQ:SPNC) closed its last trading session 00.00 at 25.15 with 182,063 shares trading hands.